Professor Tony Mok

Professor Mok has been an Independent Non-executive Director since 2017. He is also a member of our nomination committee and technical committee. Professor Mok has more than 30 years of experience in clinical oncology with his main research interest focusing on biomarker and molecular targeted therapy in lung cancer.  He is currently Li Shu Fan Medical Foundation named professor and chairman of department of clinical oncology at The Chinese University of Hong Kong. Professor Mok has contributed to over 200 articles in international peer-reviewed journals, as well as multiple editorials and textbooks. In 2018, Professor Mok was the first Chinese to be bestowed with the European Society of Clinical Oncology (ESMO) Lifetime Achievement Award, one of the most prestigious international honours and recognitions given to cancer researchers, for his contribution to and leadership in lung cancer research worldwide. He is an independent non-executive director of AstraZeneca Plc, which is listed on the main market of the London Stock Exchange (stock code: AZN), a director of the American Society of Clinical Oncology (“ASCO”), a member of the ASCO Publications Committee and vice chairman of the Chinese Society of Clinical Oncology (“CSCO”). He also formerly chaired the ASCO International Affairs Committee. Professor Mok is closely affiliated with the oncology community in China and has been awarded an Honorary Professorship at Guangdong Province People’s Hospital and Visiting Professorship at Shanghai Jiao Tong University and West China School of Medicine/West China Hospital, Sichuan University. He received his Bachelor of Medical Science degree in 1982 and a Doctor of Medicine from University of Alberta, Canada. He has also been a Fellow of the Royal College of Physicians and Surgeons of Canada since 1988, Hong Kong College of Physicians since 1996, Hong Kong Academy of Medicine since 1997, Royal College of Physicians of Edinburgh since 2014 and ASCO since 1996.